Mesocarb (brand names Sidnocarb, Sydnocarb) is a drug that is currently being developed for Parkinson's disease. The drug was originally developed in the USSR in the 1970s for a variety of indications including asthenia, apathy, adynamia and some clinical aspects of depression and schizophrenia. It has been found to act as a selective dopamine reuptake inhibit and is less potent and slower-acting but longer-lasting than dextroamphetamine.
Mesocarb: Mesocarb (brand names Sidnocarb... - Cure Parkinson's
Mesocarb
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Not what you're looking for?
You may also like...
Will Tasigna, an FDA-approved cancer drug, be the first drug to revere symptoms of Parkinson's and dementia?
At their best, drugs for Parkinson's disease (PD) only slow the progression of the disease. But...
Researchers in Japan have developed a technique to visualize how an abnormal protein accumulates in brains of PP patients
This is an important development
It has been known that a protein called alpha-synuclein builds up...
Promising news from Australia for a breakthrough treatment for Parkinson's disease
The New Daily
There’s quiet but confident hope for a breakthrough treatment for Parkinson’s...
Improving the Bio-availability of Levodopa
This is a simplified version of my research into how L-Dopa is metabolised in humans and my current...
GV-971 For Alzheimer's Disease Now and PD Later Next Year....maybe
Although this study is about Alzheimer's Disease (AD), it is very interesting in showing how the...
Related Posts
The way to a patients head is through there stomach
Getting stuff across the BBB & exactly where you want it in the brain - through the nose, with ultrasound (in mice)
Tamsulosin, and interesting paper on genetic variants affecting side effects- Parkinsons Disease and Exercise
Clinical trial suggests Parkinson's drug is safe in humans
